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Abstract: Aims 
In radiotherapy trials normal tissue effects (NTE) are important 
endpoints, and it is pertinent to ask whether patient reported outcome 
measures (PROMs) could replace clinical and/or photographic assessments. 
Data from the START breast radiotherapy trials are examined. 
 
Materials and Methods 
NTEs in the treated breast were recorded by i) annual clinical 
assessments, ii) photographs at 2 and 5 years, iii) PROMs at 6 months, 1, 
2 and 5 years following radiotherapy. Hazard ratios for the radiotherapy 
schedules were compared. Measures of agreement of assessments at 2 and 5 
years tested concordance. 
  
Results 
PROMs were available at 2 and/or 5 years for 1939 women, of whom 1870 had 
clinical and 1444 had photographic assessments. All methods were 
sensitive to the dose difference between schedules. Patients reported 
higher prevalence for all NTE endpoints than clinicians or photographs 
(p<0.001 for most NTEs). Concordance was generally poor; weighted kappa 
at 2 years ranged from 0.05 (telangiectasia) to 0.21 (shrinkage and 
oedema). Percentage agreement was lowest between PROMs and photographic 
assessments of change in breast appearance (38%). 
  
Conclusions 
All 3 methods produced similar conclusions for the comparison of trial 
schedules, despite low concordance between the methods on an individual 
patient basis. Careful consideration should be given to the different 
contributions of the measures of NTE in future radiotherapy trials. 
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Article Title: Do patient-reported outcome measures agree with clinical and photographic assessments of 
normal tissue effects after breast radiotherapy? The experience of the Standardisation of Breast 
Radiotherapy (START) Trials in early breast cancer 
 
In response to the editor’s comment, we have added the following reference to the introduction (page 3): 
"Patient-reported outcome measures in radiotherapy: clinical advances and research opportunities in 
measurement for survivorship" by S Faithfull, A Lemanska, T Chen.  published in CO vol. 27 issue 11 Nov. 
2015 pgs. 679-685. 
 
Response to reviewers: 
 
Reviewer #1: The paper from Haviland and colleagues reports on the relationships between the methods 
(patient recorded outcomes, clinical assessments and photographic assessments) used to determine 
normal tissue effects (NTEs) in the START A & B trials.  These ground breaking studies have been critical in 
challenging previously accepted dogma (largely unsupported by substantive randomized evidence) 
concerning normal tissue sensitivity to fraction size in  breast radiotherapy and have lead to the 
rationalization of radiotherapy treatment approaches at an international level.   
The START triallists made serious efforts to collect information on NTEs - which determine the cosmetic 
consequences of breast radiotherapy - and provide here a useful comparison between these methods.  
Their findings that the three methods produce similar 'trial level' estimates of NTEs, but that there is 
relatively poor 'individual patient-level' correlation are of critical importance for the conduct of future 
studies as well as the interpretation of the START trial results.  The move towards patient reported 
outcomes in the anticipation that such outcomes are predominant (and may be less resource-demanding 
to collect)  needs to be tempered with an understanding of how these endpoints relate to the more 
traditional endpoints conventionally reported in prospective studies. 
 
We thank the reviewer for their supportive comments. 
 
Reviewer #2: This is a timely paper with follow-up becoming ever my pressured in UK hospitals. The ability 
to consider PROMs and clinical photographs as the accepted measures of NTEs would be an important 
advance. I have minor comments only: 
1. Abstract results page2, bracket should be after "(p<0.001" in the following sentence: Patients reported 
higher prevalence than clinicians or photographs (p<0.001 for most NTEs). 
The text as written in our original manuscript is correct. Patient-reported prevalences were higher for all 
NTEs looked at in the analysis – “for most NTEs” refers to the p-value. The text has been revised to clarify 
this. 
 
2. Acronym NTE incorrectly used in first sentence of introduction, "Traditional outcome measures of 
normal tissue responses (NTE) ....". Correctly explained later same paragraph. 
This has been corrected on page 3 of the manuscript. 
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3. In the Introduction patient-reported outcome measures (PRO) in ….. should this be PROM? This is a 
question for the authors to consider. 
We have changed PRO to PROM throughout the manuscript. 
 
4. Ist line of materials and methods: The START-A and START-B trials recruited 4451 women between 1998 
and 1993 from 35 …… I think you mean 2003 not 1993 
It should read “from 1998 to 2002”; we have corrected this on page 4 of the manuscript. 
 
5. Page 4: Trial-B patients were randomised to either 50 Gy in 25 fractions over 5 weeks (control) or 40 Gy 
in 15 fractions of 2.7 Gy over 3 weeks. Full details of the recruitment, and radiotherapy planning, delivery 
and verification protocols have been previously reported, as has the PRO study [11-13]. I think references 
should be 11-14 
We have corrected this on page 4. 
 
Reviewer #3: This study compares different methods of assessing changes in breast appearance using data 
from patients recruited from the START trials.  
The data are presented satisfactorily, and agreement (concordance) between methods (using simple 
percentage agreement, weighted Kappa and Bowker's test) is analysed appropriately. 
However, the choice of the statistical methodology used for the comparison of treatment effects is unclear, 
and the Abstract requires some amendments (see below).  
1.    Cox proportional hazards regression was used to analyse treatment effects (moderate/marked vs 
none/a little) between schedules (Figures 1 and 2).  Why was this type of analysis used? Cox regression is 
conventionally used for censored time data (where study subjects have differing follow-up times). In this 
study, follow-up time (between assessments) is surely constant? If so, why wasn't logistic regression, 
which is used for binary outcome data measured at a specific follow-up point, used? 
The results presented in Figures 1 and 2 use all available NTE data from the trials (as in the original trial 
publications) and not just the 2 and 5-year assessments used in the analyses of concordance of individual 
scores – i.e. at 6 months, 1, 2 and 5 years for PROMS, annually for the clinical assessments and at 2 and 5 
years for photographs.  These data were then analysed as time to first NTE event, hence why Cox regression 
was used. Text has been added to the statistical methods section on page 6 to clarify this. 
 
2.    Abstract. "Patients reported higher prevalence than clinicians or photographs…".   
This statement is ambiguous as it stands. What outcome is being referred to here? 
This has now been clarified in the text, as discussed in response to reviewer #2’s first comment. 
 
3.    Abstract. "Concordance between the methods on an individual patient basis was low, but this does 
not prevent PRP and photographs being considered as the primary measure of NTE in future radiotherapy 
trials". 
I am not convinced that this is a reasonable summary of the results. The Discussion appears to be saying 
that PRO and photographs complement the clinical findings, not that they should take priority? 
The conclusions in the abstract have been revised. 
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Abstract  
Aims 
In radiotherapy trials normal tissue effects (NTE) are important endpoints, and it is 
pertinent to ask whether patient reported outcome measures (PROPROMs) could 
replace clinical and/or photographic assessments. Data from the START breast 
radiotherapy trials are examined. 
Materials and Methods 
NTEs in the treated breast were recorded by i) annual clinical assessments, ii) 
photographs at 2 and 5 years, iii) PROPROMs at 6 months, 1, 2 and 5 years 
following radiotherapy. Hazard ratios for the radiotherapy schedules were compared. 
Measures of agreement of assessments at 2 and 5 years tested concordance.  
Results 
PROPROMs were available at 2 and/or 5 years for 1939 women, of whom 1870 had 
clinical and 1444 had photographic assessments. All methods were sensitive to the 
dose difference between schedules. Patients reported higher prevalence for all NTE 
endpoints than clinicians or photographs (p<0.001 for most NTEs). Concordance 
was generally poor; weighted kappa at 2 years ranged from 0.05 (telangiectasia) to 
0.21 (shrinkage and oedema). Percentage agreement was lowest between 
PROPROMs and photographic assessments of change in breast appearance (38%).  
Conclusions 
All 3 methods produced similar conclusions for the comparison of trial schedules, 
despite low . Cconcordance between the methods on an individual patient basis.  
was low, Careful consideration should be given to the different contributions of the 
measures of NTE but this does not prevent PRO and photographs being considered 
as the primary measures of NTE in future radiotherapy trials. 
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Introduction 
Traditional outcome measures of normal tissue responses (NTE) to radiotherapy rely 
heavily, often exclusively, on clinical assessments using graded scales to score a 
wide range of early and late adverse effects [1-4]. Scoring systems, including Late 
Effects in Normal Tissues Subjective, Objective, Management and Analytic (LENT-
SOMA), Radiation Therapy Oncology Group (RTOG) and Common Terminology 
Criteria for Adverse Events (CTCAE), feature symptomatology requiring health 
professionals to elicit and score responses to direct questions. Photographic 
assessments of change in breast appearance from a pre-radiotherapy baseline have 
become increasingly used in randomised trials of radiotherapy as they are usually 
scored by a small number of observers blinded to patient identity, treatment 
allocation and year of follow-up, unlike the clinical assessments which are scored by 
a large number of individuals in a multi-centre study [5]. In parallel, the use of 
carefully developed and validated quality of life instruments in psychosocial research 
and phase III cancer clinical trials has expanded considerably [6-8], together with the 
growing interest in use of PROMS in routine follow-up [9][ ]. With an increasing use 
of patient-reported outcome measures (PROPROMs) in cancer clinical trials [10, 11], 
it is worth asking how comparable and interpretable are the different methods of 
assessment, and whether PROPROMs could become the primary means of scoring 
late normal tissue effects (NTE) of breast radiotherapy in trials. Against this 
background, the large-scale UK START randomised trials [12-15] of 
hypofractionated radiotherapy after primary surgery for early breast cancer were 
used to conduct exploratory analyses comparing different methods of assessment of 
late NTE after adjuvant breast radiotherapy with the primary aim of assessing if 
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PROPROMs might take priority over, or replace, clinical and/or photographic 
assessments as outcome measures. 
Materials and Methods 
The START-A and START-B trials recruited 4451 women between 1998 and 1993 
2002 from 35 UK radiotherapy centres (ISRCTN59368779, MREC(1)98/86). Centres 
could opt to participate in the PROPROMs and photographic assessment studies, 
and if they participated, they were expected to invite every eligible trial patient to join. 
Thirty one (89%) centres opted to participate in the PROPROMs study and 29 (83%) 
in a photographic assessment study of change in breast appearance. Women with 
operable invasive breast cancer (International Union Against Cancer pT1-3a pN0-1 
M0) requiring radiotherapy after surgery (breast-conserving surgery or mastectomy, 
with clear tumour margins ≥1 mm) were eligible for the trials if they were aged over 
18 years, did not have an immediate surgical reconstruction, and were available for 
follow-up. Trial-A patients were randomised to either 50 Gy in 25 fractions (control) 
or 41.6 Gy in 13 fractions of 3.2 Gy or 39.0 Gy in 13 fractions of 3.0 Gy over 5 
weeks. Trial-B patients were randomised to either 50 Gy in 25 fractions over 5 weeks 
(control) or 40 Gy in 15 fractions of 2.7 Gy over 3 weeks. Full details of the 
recruitment, and radiotherapy planning, delivery and verification protocols have been 
previously reported, as has the PROPROMs study [12-14]. 
 
Patients in the PROPROMs study completed baseline measures in clinic and were 
sent questionnaires to complete at home at 6 months, 1, 2 and 5 years following 
radiotherapy. Clinical assessments of NTE were collected at annual follow-up in all 
patients, and photographs were taken under standard conditions at post-surgical 
pre-radiotherapy baseline and at 2 and 5 years post-randomisation for patients who 
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had breast conserving surgery. The patient questionnaires included the i) EORTC 
QLQ-C30 core questionnaire and QLQ-BR23 breast-specific module [6, 16], from 
which the assessment of breast swelling over the previous 4 weeks (not at all, a little, 
quite a bit, very much) was used in this study of concordance, ii) Hospital Anxiety 
and Depression Scale [17], iii) 10-item Body Image Scale [18] and iv) 4 protocol-
specific questions asking patients to score “change in breast appearance”, “breast 
hardness/firmness”, “reduction in size of breast” and “change in skin appearance” 
since radiotherapy; the first three questions applying only to patients with conserved 
breasts, and all items scored on a 4-point scale (none, a little, quite a bit, very much). 
 
The annual clinical assessments of breast shrinkage, breast induration, 
telangiectasia and breast oedema were scored using the contralateral breast as a 
comparator and 4-point graded scales (none, a little, quite a bit, very much). Change 
in photographic breast appearance since radiotherapy was scored by a single team 
of 3 observers blind to patient identity, trial treatment allocation, year of follow-up and 
radiotherapy centre. The scoring method was validated in the START pilot trial [5]. 
Photographs at 2 and 5 years following radiotherapy were compared with a pre-
radiotherapy (post-surgery) baseline and an overall score allocated for change in 
photographic breast appearance in the treated breast based on change in size, 
shrinkage and shape, on a 3-point scale (no change, mild change, marked change). 
Post-mastectomy patients were included in the PROPROMs and clinical 
assessments but not in the photographic assessments. Individual NTE were mapped 
between the different assessment methods in order to compare corresponding 
outcomes, as shown in Table 1. 
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Statistical methods  
NTE assessments at all time-points in the trials were included in the comparison of 
radiotherapy schedules (i.e. from 6 months-5 years for the PROMSs, from 1-5 years 
for the clinical assessments, and at 2 and 5 years for the photographs). Time to first 
NTE event (defined as “quite a bit” or “very much” for the PROMs and clinical 
assessments, and any change (mild or marked) in photographic breast appearance) 
was calculated from date of randomisation, and survival analysis methods used to 
compare radiotherapy schedules. The hHazard ratios (HR) for the relative effects of 
the radiotherapy schedules in START-A were calculated for each NTE endpoint 
using Cox proportional hazards regression and compared between the different 
assessment methods using forest plots. Estimates of the α/β ratio for NTEs, which 
describes the sensitivity of normal tissues to fraction size, were obtained separately 
for the PROPROMs, clinician and photographic endpoints in START-A. Estimates of 
relative effects of the fractionation schedules in START-B are not presented in this 
paper as they do not contribute to the measurement of fraction sensitivity, only 
having two randomised groups in Trial B. HRs for the fractionation schedules in 
START-B have been published separately for the different NTE assessments, and 
showed consistent results [13-15].  
 
For the concordance analyses, data from START Trials A and B were combined, and 
only 2 and 5-year assessments included as these were the time-points at which all 
three NTE assessment methods were used in the trials. For all PROPROMs and 
clinically-assessed endpoints there were few patients in the highest grade category, 
so moderate and marked categories were combined, resulting in 3-point scales 
corresponding to none, a little (“mild”), quite a bit / very much (“moderate / marked”); 
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this also enabled comparison with the photographic assessments, which were 
scored on a similar 3-point scale. Corresponding NTE endpoints were matched 
between the PROPROMs, clinical and photographic assessments at each time point 
and compared on an individual patient basis using measures of concordance 
including percentage agreement (with 95% confidence interval, CI), weighted Kappa 
statistic (with 95%CI) and Bowker’s test of symmetry [19]. Guidelines for interpreting 
the value of the weighted Kappa statistic in terms of the strength of agreement are 
<0.20: poor, 0.21-0.40: fair, 0.41-0.6: moderate, 0.61-0.8: good, 0.81-1.00: very good 
[20]. Bowker’s test assesses the symmetry of a square table – i.e. whether there are 
more observations on one side of the diagonal than the other. The concordance 
analyses were also carried out stratifying on baseline patient characteristics such as 
age and quality of life scores (including anxiety and depression from the Hospital 
Anxiety and Depression Scale and body image from the Body Image Scale), to 
investigate whether these had any effect on the degree of concordance between 
NTE assessment methods.  
 
Results 
Of the 2208 women recruited into the overall START Trials PROPROMs study, self-
assessments of NTEs were available at 2 and/or 5 years for 1939 (88%) patients, of 
whom 1870 also had clinical assessments at the same time-points (85% of all 
patients in PROPROMs study). Patient characteristics at baseline for the 1870 
patients in this analysis are shown in Table 2, of whom 1574/1870 (84.2%) had 
breast conserving surgery and 1444/1574 (91%) had photographic assessments at 2 
and/or 5 years. 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
9 
 
Treatment effects on late NTE assessed by PROPROMs and by annual clinical 
assessment in START-A are shown side-by-side in Figure 1. Two test schedules 
(41.6 Gy and 39 Gy in 13 fractions) were compared with control (50 Gy in 25 
fractions) in START-A. Comparing HR for corresponding endpoints, it can be seen 
that the treatment effects were of a similar size for PROPROMs and clinical 
assessments, with overlapping confidence intervals. Treatment effects on late NTE 
assessed by PROPROMs and by photographs for overall change in breast 
appearance were also similar (Figure 2). α/β estimates (adjusted for prognostic 
factors) for overall change in breast appearance were 2.9 Gy (95%CI 0.7-5.1 Gy) for 
PROPROMs and 2.6 Gy (95%CI 1.3-3.9 Gy) for photographic assessments. α/β 
estimates for individual NTE endpoints from clinical assessments have been 
reported [14] (there was no clinical assessment of overall cosmesis in the START 
Trials).  
 
The comparison of overall rates of NTEs reported by PROPROMs and clinical 
assessments from START Trials A and B combined showed that patients reported a 
higher prevalence of breast changes (Figures 3a-d). Concordance between the 
assessments of corresponding NTEs on an individual patient basis was generally 
poor (Table 3). The lowest levels of percentage agreement between PROPROMs 
and clinicians were observed for breast induration / hardness (47% and 50% at 2 
and 5 years, respectively), and breast shrinkage (53% and 47% at 2 and 5 years). 
The highest level of percentage agreement between PROPROMs and clinicians was 
for breast swelling/oedema (78% and 86% at 2 and 5 years), but the overall 
prevalence of oedema was very low (Figure 3c). Weighted kappa statistics also 
highlighted the low agreement between methods, ranging from 0.05 for 
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telangiectasia at 2 years (indicating poor agreement) to 0.21 for each of breast 
shrinkage and breast oedema at 2 years (indicating fair agreement). Results of 
Bowker’s test of symmetry were highly statistically significant for all NTE endpoints, 
indicating a clear direction in the discordance of scoring between the different 
methods, with patients reporting more breast changes compared with clinical and 
photographic assessments (Table 3). There appeared to be no substantial 
differences in degree of concordance for individual NTE endpoints according to time 
since radiotherapy i.e. between 2 and 5 years (Table 3). 
 
The comparison of PROPROMs and photographic assessments showed that 
patients reported a higher prevalence of overall change in breast appearance since 
radiotherapy and graded effects as more severe compared with the photographic 
assessments (Figure 3e). In testing concordance, agreement on an individual patient 
basis was low at 2 and 5 years (38% for each), with low weighted kappa values 
(0.09) and highly statistically significant discordance (p<0.001 for Bowker’s test of 
symmetry); Table 3. Concordance of PROPROMs with clinical and photographic 
assessments of NTE appeared to be unaffected by patient factors including age, 
breast size, surgical deficit, baseline HADS anxiety and depression and body image 
scores (table in web appendix). 
 
Discussion 
Concordance between PROPROMs and NTE assessments as scored by clinicians 
and from photographs on an individual patient basis was poor. Percentage 
agreement between PROPROMs and clinical assessments of specific NTEs was 
around 50%, indicating that in only half of the patients the NTE was graded in the 
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same category of severity corresponding to none, mild, moderate/marked. 
Agreement was even lower between PROPROMs and photographs, where less than 
40% graded NTEs the same. In our study, patients scored NTEs more frequently 
and more severely than results from clinicians or photographs. Concordance did not 
appear to be affected by patient characteristics including psychological measures 
(anxiety and depression), body image and factors associated with risk of NTEs (age, 
breast size and surgical deficit). It may not be surprising that concordance between 
the assessment methods on an individual patient basis was poor; this has been 
consistently reported in other studies [21-24]. These differences in ratings reflect the 
different paradigms in which symptoms are perceived and rated; these include 
variance in context, values, expectations and methodological influences as well as 
the different sociocultural backgrounds of subjects and doctors [25]. Published 
comparisons of clinician and patient self-assessments show considerable variability 
between ratings, especially for more subjective symptoms and often report, as in our 
study, a relative underestimate by clinicians compared with patients (e.g. Basch et al 
[26], Bruner et al [27], Fromme et al [23], Groenwold et al [28], Quinten et al [29], 
Stephens et al [30], Velikova et al [24]). However, the concordance analysis of NTE 
assessments in the Cambridge intensity-modulated breast radiotherapy trial found 
the opposite, with clinicians and photographic assessments reporting more NTEs 
compared with patients, possibly because the study was done in  a single centre, 
with clinical ratings done by one person [31]. Others have shown more favourable 
rating of overall cosmesis following conservative treatment for breast cancer by 
patients compared with clinicians [32, 33], although these findings are not 
necessarily specific to late effects of radiotherapy. Kirchheiner et al [34] argued that 
some variation is “quite acceptable and comprehensible”, given the methodological 
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differences between morbidity scoring by clinicians and patient-reported symptoms. 
Clinical and patient symptom ratings are typically not designed to be 
interchangeable, given that they often have different values and purposes, with 
patient assessments inherently encompassing impact on quality of life.  
 
However, our study showed that despite the discordance between assessments on 
an individual basis, the three methods (PROPROMs, clinical and photographs) 
generated similar estimates of relative treatment effects on NTE within the trials [12, 
14, 15]. The discriminatory power of different assessments was equally good, in that 
PROPROMs generated the same estimates of α/β value for NTE in START-A 
(around 3 Gy) as photographs and clinical assessments (data for α/β values of 
clinical assessments of NTEs previously published [14]). From the trial outcome 
perspective, this consistency of treatment effects adds considerable weight to the 
overall interpretation and conclusions of the trial. However, the PROPROMs reported 
here were selected from a large number of multidimensional items assessed as part 
of the START quality of life sub-study, most of which would not be expected to 
discriminate so clearly between the schedules in the START trials, but are of value in 
understanding the experience of treatment effects over time. The PROPROMs items 
included in this analysis of concordance were those directly relevant to the 
hypothesis under test in the clinical trial, and therefore most likely to be sensitive to 
randomised differences in radiotherapy dose intensity. The PROPROMs needed to 
have a recognisable relationship with the pathophysiology (atrophy, fibrosis) of NTE, 
broadly corresponding to clinical scoring of change in size (atrophy), shape and 
texture (oedema, fibrosis) of the breast and change in photographic breast 
appearance (atrophy, distortion/fibrosis). This is in contrast with other clinically 
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relevant domains, such as physical and social functioning, that explore the impact on 
different aspects of quality of life [6, 16].  
 
Clinicians are taught in training that symptomatology is the key to diagnosis, which 
they can only judge by listening to their patients and framing relevant questions. 
Clinicians act as surrogates for their patients in this context, so that if the relevant 
questions are known in advance (as they are in a clinical trial), there appears to be a 
good reason to prioritise the PROPROMs over the physical clinical assessments. 
Where physical signs are concerned, including breast size, shape and texture, this 
study suggests that patients are as sensitive as their doctors in scoring these 
changes too, provided the questions are framed appropriately. In this respect, it is 
possible to criticise our PROPROMs question, which asked patients to score 
changes since radiotherapy to the affected breast compared with the clinical 
assessment that compared the treated with the untreated breast at the time of the 
annual examination. Despite a variety of factors expected to influence how a woman 
responds to this question, the sensitivity to randomised dose indicates that the 
radiotherapy ‘signal’ was not lost. Doctors also develop their own frames of 
reference when assessing NTE, and the hundreds of clinical observers involved in 
scoring NTE in thousands of patients over a 10-year period, as in the START trials, 
necessarily contribute a lot of ‘noise’ in a scoring system. However, a disadvantage 
of reliance on PROPROMs in clinical trials is that they are traditionally labour-
intensive to administer and generate large volumes of data, making heavy demands 
on trial management and statistical resources. Since modern data capture systems 
are increasingly able to collect outcome data directly from the patient (e.g. via an 
App), dispensing with clinical follow-up may appeal to patients as well as health 
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services operating under increasing pressures [35]. However, radiation effects are 
not viewed in isolation by patients and attention also needs to be paid to their 
concerns in the context of multi-modal treatments and adverse effects over time. Up 
to a third of patients report moderate or marked symptoms of the breast, arm and 
shoulder at 5 years, which may warrant engagement and advice from their clinical 
teams [13]. Thus more preparation and after care is needed for the success of 
patient self-management post-treatment and to improve quality of life [36]. Further, 
the acceptability of electronic symptom-reporting warrants evaluation in an aging 
population. 
 
Despite adding to the administrative burden of clinical trials, the photographic 
assessments of NTEs provide valuable information, not least because they are 
scored generally by the same small team of observers who are blind to patient 
identity, randomised treatment allocation, year of follow-up and participating hospital. 
As it is generally not possible to blind treatment allocation in radiotherapy trials the 
photographic assessments provide the only unbiased comparison of normal tissue 
effects between randomised groups. In addition, as photographs provide a 
permanent record of breast effects at a fixed point in time, the assessments can be 
validated by repeat scoring from different teams of observers [5], thus making the 
scoring more standardised than PROPROMs or clinical assessments from physical 
examination. Photographs can also be filed and stored for use in future translational 
research investigating adverse effects of radiotherapy. There are some 
disadvantages to the use of photographic assessments in clinical trials, including 
financial and staff resources required, and they can be disliked by patients, but these 
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are outweighed by the benefits of retaining an unbiased comparison of NTEs within 
radiotherapy trials.  
 
There is growing interest in investigating inherited risk factors for radiotherapy NTE, 
for which robust measures of NTE are needed that have a close relationship to the 
underlying pathophysiology [37], In this respect, the lack of concordance reported in 
this study is intriguing and potentially worrying. The prevalence and severity of NTEs 
reported by patients, clinicians and from photographs during follow-up were widely 
discordant in most cases. In trying to identify subgroups of patients with levels of 
NTE that are much more, or much less, severe than expected on the basis of known 
factors (breast size, radiotherapy dose etc.), it isn’t possible to judge whether the 
clinical and photographic assessments of NTE severity are more or less valid than 
the PROPROMs, hence making identification of potential cases (and controls) for 
translational studies very difficult. Perhaps much depends on how the NTE 
assessment questions to patients and clinicians are posed, something that this study 
does not address. 
 
In conclusion, the PROPROMs, clinical and photographic assessments of late NTE 
in the START trials generated consistent estimates of relative treatment effects 
between randomised groups, adding weight to the trials’ overall findings. 
Discordance in the prevalence rates of NTE reported by the patients, clinicians and 
photographs could be expected for a number of well-established reasons, but this 
does not undermine an argument for prioritising PROPROMs and photographic 
assessments of NTEs in breast radiotherapy trials. 
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Figure legends 
 
Figure 1: Comparisons between randomised radiotherapy schedules in START Trial 
A for PROPROMs and clinical assessments of specific normal tissue effects 
 
Figure 2: Comparisons between randomised radiotherapy schedules in START Trial 
A for PROPROMs and photographic assessments of overall change in breast 
appearance 
 
Figure 3: Comparison of 5-year PROPROMs, clinical and photographic 
assessments of specific normal tissue effects in START Trials A and B 
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Figure 1: Comparisons between randomised radiotherapy schedules in START Trial 
A for PROPROMs and clinical assessments of specific normal tissue effects  
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Figure 2: Comparisons between randomised radiotherapy schedules in START Trial 
A for PROPROMs and photographic assessments of overall change in breast 
appearance 
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Figure 3: Comparison of 5-year PROPROMs, clinical and photographic 
assessments of specific normal tissue effects in START Trials A and B 
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Table 1: Clinical and photographic outcome measures of specific late normal tissue 
effects in the breast and the corresponding PROPROM 
 
Clinical assessment of late normal 
tissue effect in the treated breast 
Corresponding PROPROM used to 
test concordance with clinical or 
photographic assessment2 
Has the patient had any of the following 
adverse effects? Compare with 
contralateral breast1: 
 
Breast shrinkage 
Has your affected breast become smaller 
as a result of your radiotherapy?4 
Breast induration 
Has your affected breast become 
harder/firmer to the touch since your 
radiotherapy?4 
Breast oedema 
During the past four weeks, was the area 
of your affected breast swollen?5 
Telangiectasia 
Has the appearance of the skin in the 
area of your affected breast changed 
since your radiotherapy?4 
Has there been a change in 
photographic breast appearance 
compared with pre-radiotherapy 
baseline photograph?3 
Has the overall appearance of your 
affected breast changed, compared with 
the other side, as a result of your 
radiotherapy?4 
 
1
 Clinical assessments scored as none, a little, quite a bit, very much 
2
 PROPROMs scored as not at all, a little, quite a bit, very much 
3
 Photographic assessments scored as no change, mild change, marked change 
4
 Protocol-specified items included in the patient questionnaire booklet under the heading “Since your 
breast radiotherapy” 
5
 Question from the EORTC QLQ-BR23 breast cancer module  
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Table 2: Baseline characteristics of 1870 START Trial A and B patients with 
PROPROMs and clinical assessments of normal tissue effects at 2 and/or 5 years 
following radiotherapy 
 Number of patients (%) 
Age (years): mean (SD) [range] 57.0 (10.0) [27.1-86.0] 
Type of primary surgery 
  Breast conserving surgery 
  Mastectomy 
 
1574 (84.2) 
296 (15.8) 
Axillary surgery 
  None 
  Axillary clearance 
  Axillary sampling 
  Sentinel node biopsy 
 
55 (  2.9) 
1284 (68.7) 
495 (26.5) 
36 (  1.9) 
Adjuvant chemotherapy 
  No 
  Yes 
  Unknown 
 
1268 (67.8) 
598 (32.0) 
4 (  0.2) 
Tamoxifen 
  No 
  Yes 
  Unknown 
 
312 (16.7) 
1554 (83.1) 
4 (  0.2) 
Breast size 
  Small 
  Medium 
  Large 
  Unknown – not in photographic study  
 
154 (  8.2) 
1126 (60.2) 
228 (12.2) 
362 (19.4) 
Surgical deficit 
  Small 
  Medium 
  Large 
  Unknown – not in photographic study 
 
872 (46.6) 
496 (26.5) 
140 (  7.5) 
362 (19.4) 
Hospital Anxiety and Depression Scale  
Anxiety 
  Normal (0-7) 
  Borderline (8-10) 
  Case (11+) 
  Unknown 
 
1287 (68.8) 
322 (17.2) 
256 (13.7) 
5 (  0.3) 
Depression 
  Normal (0-7) 
  Borderline (8-10) 
  Case (11+) 
  Unknown 
 
1658 (88.7) 
152 (  8.1) 
52 (  2.8) 
8 (  0.4) 
Body Image Scale (10-items): median (IQR) [range] 3 (0-8) [0-30] 
 
SD = standard deviation; IQR = interquartile range 
Breast size and surgical deficit assessed from baseline photographs 
HADS scales range from 0-21 
Body Image Scale ranges from 0-30, where a higher score indicates more concerns; unknown for 79 
patients 
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Table 3: Concordance between PROPROMs and clinical or photographic 
assessments of specific normal tissue effects at 2 and 5 years in START Trials A 
and B 
 
Clinicians Patients % 
agreement 
(95%CI) 
Weighted 
Kappa 
(95%CI) 
Bowker’s 
test of 
symmetry, 
p-value 
None A  
little 
Quite 
a bit 
/very 
much 
Breast shrinkage
1
 – 2 years 755/1413; 
53.4% 
(50.8-56.1%) 
0.21 
(0.17-0.25) 
<0.001 
None 566 335 83 
A little 107 158 70 
Quite a bit / very much 18 45 31 
Breast shrinkage
1
 – 5 years 579/1221; 
47.4% 
(44.6-50.3%) 
0.19 
(0.15-0.24) 
<0.001 
None 372 277 126 
A little 96 151 87 
Quite a bit / very much 18 38 56 
 
Breast induration / hardness
1
 – 2 years 676/1439 
47.0% 
(44.4-49.6%) 
0.12 
(0.08-0.16) 
<0.001 
None 493 379 136 
A little 112 152 73 
Quite a bit / very much 31 32 31 
Breast induration / hardness
1
 – 5 years 610/1222; 
49.9% 
(47.1-52.8%) 
0.12 
(0.07-0.16) 
<0.001 
None 482 295 94 
A little 121 105 40 
Quite a bit / very much 22 40 23 
 
Breast oedema / swelling
1
 – 2 years 1144/1465; 
78.1% 
(75.9-80.2%) 
0.21 
(0.15-0.26) 
0.017 
None 1092 146 21 
A little 109 51 9 
Quite a bit / very much 16 20 1 
Breast oedema / swelling
1
 – 5 years 1089/1260; 
86.4% 
(84.4-88.2%) 
0.10 
(0.04-0.17) 
0.003 
None 1076 86 19 
A little 54 13 3 
Quite a bit / very much 6 3 0 
 
Telangiectasia / change in skin appearance
2
 – 2 years 959/1721; 
55.7% 
(53.3-58.1%) 
0.05 
(0.02-0.07) 
<0.001 
None 911 572 134 
A little 32 42 11 
Quite a bit / very much 6 7 6 
Telangiectasia / change in skin appearance
2
 – 5 years 900/1446; 
62.2% 
(59.7-64.7%) 
0.08 
(0.04-0.12) 
<0.001 
None 859 369 90 
A little 47 30 16 
Quite a bit / very much 13 11 11 
 
Photographs 
Overall change in breast appearance
1
 – 2 years 489/1290; 
37.9% 
(35.3-40.6%) 
0.09 
(0.06-0.11) 
<0.001 
None 331 525 130 
Mild 56 141 78 
Marked 4 8 17 
Overall change in breast appearance
1
 – 5 years 409/1064; 
38.4% 
(35.5-41.4%) 
0.09 
(0.06-0.12) 
<0.001 
None 258 344 123 
Mild 66 140 108 
Marked 5 9 11 
 
CI = confidence interval 
1
 breast conserving surgery patients only 
2
 breast conserving surgery and mastectomy patients
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Web Appendix: Concordance between PROPROMs and clinical or photographic assessments of specific normal tissue effects at 5 years stratified by 
baseline patient characteristics in START Trials A and B 
 Breast shrinkage
1
 Breast induration/hardness
1
 Breast oedema/swelling
1
 Telangiectasia/change in 
skin appearance
2
 
Overall change in breast 
appearance
1
 
% agreement 
(95%CI) 
Weighted 
Kappa (95%CI) 
% agreement 
(95%CI) 
Weighted 
Kappa (95%CI) 
% agreement 
(95%CI) 
Weighted 
Kappa 
(95%CI) 
% agreement 
(95%CI) 
Weighted 
Kappa 
(95%CI) 
% 
agreement 
(95%CI) 
Weighted 
Kappa 
(95%CI) 
Age 
<50 years 
 
>50 years 
 
43.7  
(37.5-50.0) 
48.4  
(45.2-51.6) 
 
0.22  
(0.14-0.31) 
0.20  
(0.15-0.25) 
 
47.4  
(41.2-53.8) 
50.6  
(47.4-53.8) 
 
0.09  
(0.01-0.17) 
0.13  
(0.08-0.18) 
 
N/A 
 
86.9  
(84.6-88.9) 
 
N/A 
 
0.12  
(0.05-0.20) 
 
56.7  
(50.9-62.3) 
63.7  
(60.9-66.5) 
 
0.06  
(0.001-0.12) 
0.09  
(0.05-0.14) 
 
37.6 
(30.9-44.8) 
39.2 
(35.9-42.7) 
 
0.05 
(0-0.12) 
0.11 
(0.07-0.15) 
Breast size 
Small 
 
Medium 
 
Large 
 
 
52.8  
(43.7-61.8) 
48.9  
(45.5-52.2) 
37.8 
(30.8-45.5) 
 
0.13  
(0-0.26) 
0.22  
(0.17-0.27) 
0.10  
(0-0.21) 
 
59.8  
(50.5-68.5) 
49.8  
(46.4-53.1) 
44.6 
(37.2-52.3) 
 
0.06  
(0-0.19) 
0.11 
(0.05-0.16) 
0.10  
(0-0.21) 
 
N/A 
 
87.1  
(84.6-89.2) 
80.5  
(73.9-85.8) 
 
N/A 
 
0.06  
(0-0.13) 
0.20  
(0.05-0.36) 
 
N/A 
 
62.9 
(59.6-66.1) 
48.7 
(41.3-56.0) 
 
N/A 
 
0.05  
(0.01-0.10) 
0.07 
(0-0.16) 
 
41.2 
(32.2-50.8) 
38.2 
(34.7-41.7) 
36.9 
(29.5-45.0) 
 
0.02 
(0-0.06) 
0.08 
(0.05-0.12) 
0.06 
(0-0.17) 
Surgical deficit 
Small 
 
Medium 
 
Large 
 
 
50.9 
(47.1-54.7) 
43.9  
(38.8-49.1) 
39.3 
(30.3-49.0) 
 
0.21  
(0.15-0.26) 
0.16 
(0.08-0.23) 
0.12 
(0-0.24) 
 
50.1 
(46.3-53.8) 
53.0 
(47.7-58.1) 
40.0 
(30.9-49.8) 
 
0.10  
(0.04-0.15) 
0.20 
(0.11-0.29) 
N/A 
 
84.9 
(82.1-87.4) 
90.8  
(87.3-93.4) 
82.0 
(73.3-88.4) 
 
0.06  
(0-0.14) 
0.28 
(0.12-0.44) 
N/A 
 
62.6 
(58.9-66.2) 
60.8 
(55.7-65.8) 
60.0 
(50.2-69.1) 
 
0.08 
(0.03-0.13) 
0.03 
(0-0.10) 
0.10 
(0-0.23) 
 
40.5 
(36.7-44.6) 
36.9 
(31.9-42.3) 
28.9 
(20.3-39.1) 
 
0.10 
(0.06-0.14) 
0.08 
(0.01-0.14) 
N/A 
HADS anxiety 
0-7 (normal) 
 
8-10 
(borderline) 
>11 (case) 
 
 
50.9 
(47.5-54.3) 
43.2 
(36.4-50.3) 
35.0 
(27.7-43.0) 
 
0.22 
(0.17-0.27) 
0.14 
(0.05-0.22) 
0.13 
(0.04-0.22) 
 
52.2 
(48.8-55.6) 
46.1 
(39.2-53.2) 
42.5 
(34.8-50.1) 
 
0.12 
(0.07-0.18) 
0.12 
(0.03-0.22) 
0.09 
(0-0.19) 
 
89.0 
(86.7-90.9) 
81.2 
(75.2-86.1) 
N/A 
 
0.09 
(0-0.17) 
0.23 
(0.08-0.38) 
N/A 
 
65.6 
(62.6-68.5) 
56.7 
(50.3-63.0) 
51.1 
(43.7-58.4) 
 
0.07 
(0.03-0.12) 
0.10 
(0-0.20) 
0.08 
(0-0.17) 
 
40.3 
(36.8-43.9) 
34.8 
(28.0-42.2) 
32.1 
(24.3-40.9) 
 
0.09 
(0.05-0.13) 
0.08 
(0.01-0.15) 
0.07 
(0-0.15) 
HADS 
depression 
0-7 (normal) 
 
8-10 
(borderline) 
>11 (case) 
 
 
 
48.2 
(45.2-51.2) 
40.9 
(30.7-51.9) 
43.7 
(26.8-62.1) 
 
 
0.19 
(0.15-0.24) 
0.15 
(0.01-0.29) 
0.26 
(0.07-0.46) 
 
 
51.4 
(48.4-54.4) 
31.8 
(22.5-42.7) 
46.9 
(29.5-65.0) 
 
 
0.13 
(0.08-0.18) 
N/A 
 
0.21 
(0-0.48) 
 
 
87.9 
(85.8-89.7) 
70.0 
(59.3-79.0) 
N/A 
 
 
0.13 
(0.06-0.21) 
N/A 
 
N/A 
 
 
64.5 
(61.9-67.1) 
43.2 
(34.0-53.0) 
37.5 
(23.2-54.2) 
 
 
0.09 
(0.04-0.13) 
0.06 
(0.02-0.11) 
0.05 
(0-0.19) 
 
 
38.7 
(35.6-41.9) 
38.0 
(27.5-49.6) 
25.9 
(11.9-46.6) 
 
 
0.08 
(0.05-0.12) 
0.13 
(0.04-0.23) 
N/A 
Body Image 
Scale
3
 
0-3 
 
>3 
 
 
 
52.2 
(48.4-56.1) 
41.3 
(37.0-45.7) 
 
 
0.24 
(0.18-0.30) 
0.14 
(0.08-0.20) 
 
 
53.9 
(50.1-57.7) 
43.6 
(39.3-48.1) 
 
 
0.14 
(0.07-0.20) 
0.08 
(0.01-0.14) 
 
 
88.5 
(85.9-90.8) 
83.7 
(80.2-86.7) 
 
 
0.15 
(0.05-0.25) 
0.05 
(0-0.13) 
 
 
66.2 
(62.7-69.9) 
57.8 
(53.9-61.7) 
 
 
0.07 
(0.01-0.13) 
0.08 
(0.03-0.13) 
 
 
40.5 
(36.6-44.6) 
35.0 
(30.6-39.7) 
 
 
0.09 
(0.04-0.14) 
0.09 
(0.05-0.13) 
CI = confidence interval; N/A = not available  
1
 breast conserving surgery patients only 
2
 breast conserving surgery and mastectomy patients 
3
 10-item Body Image Scale (possible range 0-30; median baseline score = 3) 
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Abstract  
Aims 
In radiotherapy trials normal tissue effects (NTE) are important endpoints, and it is 
pertinent to ask whether patient reported outcome measures (PROMs) could replace 
clinical and/or photographic assessments. Data from the START breast radiotherapy 
trials are examined. 
Materials and Methods 
NTEs in the treated breast were recorded by i) annual clinical assessments, ii) 
photographs at 2 and 5 years, iii) PROMs at 6 months, 1, 2 and 5 years following 
radiotherapy. Hazard ratios for the radiotherapy schedules were compared. 
Measures of agreement of assessments at 2 and 5 years tested concordance.  
Results 
PROMs were available at 2 and/or 5 years for 1939 women, of whom 1870 had 
clinical and 1444 had photographic assessments. All methods were sensitive to the 
dose difference between schedules. Patients reported higher prevalence for all NTE 
endpoints than clinicians or photographs (p<0.001 for most NTEs). Concordance 
was generally poor; weighted kappa at 2 years ranged from 0.05 (telangiectasia) to 
0.21 (shrinkage and oedema). Percentage agreement was lowest between PROMs 
and photographic assessments of change in breast appearance (38%).  
Conclusions 
All 3 methods produced similar conclusions for the comparison of trial schedules, 
despite low concordance between the methods on an individual patient basis. 
Careful consideration should be given to the different contributions of the measures 
of NTE in future radiotherapy trials. 
Keywords: breast radiotherapy, normal tissue effects, patient-reported outcomes   
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Introduction 
Traditional outcome measures of normal tissue responses to radiotherapy rely 
heavily, often exclusively, on clinical assessments using graded scales to score a 
wide range of early and late adverse effects [1-4]. Scoring systems, including Late 
Effects in Normal Tissues Subjective, Objective, Management and Analytic (LENT-
SOMA), Radiation Therapy Oncology Group (RTOG) and Common Terminology 
Criteria for Adverse Events (CTCAE), feature symptomatology requiring health 
professionals to elicit and score responses to direct questions. Photographic 
assessments of change in breast appearance from a pre-radiotherapy baseline have 
become increasingly used in randomised trials of radiotherapy as they are usually 
scored by a small number of observers blinded to patient identity, treatment 
allocation and year of follow-up, unlike the clinical assessments which are scored by 
a large number of individuals in a multi-centre study [5]. In parallel, the use of 
carefully developed and validated quality of life instruments in psychosocial research 
and phase III cancer clinical trials has expanded considerably [6-8], together with the 
growing interest in use of PROMS in routine follow-up [9]. With an increasing use of 
patient-reported outcome measures (PROMs) in cancer clinical trials [10, 11], it is 
worth asking how comparable and interpretable are the different methods of 
assessment, and whether PROMs could become the primary means of scoring late 
normal tissue effects (NTE) of breast radiotherapy in trials. Against this background, 
the large-scale UK START randomised trials [12-15] of hypofractionated 
radiotherapy after primary surgery for early breast cancer were used to conduct 
exploratory analyses comparing different methods of assessment of late NTE after 
adjuvant breast radiotherapy with the primary aim of assessing if PROMs might take 
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priority over, or replace, clinical and/or photographic assessments as outcome 
measures. 
 
Materials and Methods 
The START-A and START-B trials recruited 4451 women between 1998 and 2002 
from 35 UK radiotherapy centres (ISRCTN59368779, MREC(1)98/86). Centres could 
opt to participate in the PROMs and photographic assessment studies, and if they 
participated, they were expected to invite every eligible trial patient to join. Thirty one 
(89%) centres opted to participate in the PROMs study and 29 (83%) in a 
photographic assessment study of change in breast appearance. Women with 
operable invasive breast cancer (International Union Against Cancer pT1-3a pN0-1 
M0) requiring radiotherapy after surgery (breast-conserving surgery or mastectomy, 
with clear tumour margins ≥1 mm) were eligible for the trials if they were aged over 
18 years, did not have an immediate surgical reconstruction, and were available for 
follow-up. Trial-A patients were randomised to either 50 Gy in 25 fractions (control) 
or 41.6 Gy in 13 fractions of 3.2 Gy or 39.0 Gy in 13 fractions of 3.0 Gy over 5 
weeks. Trial-B patients were randomised to either 50 Gy in 25 fractions over 5 weeks 
(control) or 40 Gy in 15 fractions of 2.7 Gy over 3 weeks. Full details of the 
recruitment, and radiotherapy planning, delivery and verification protocols have been 
previously reported, as has the PROMs study [12-14]. 
 
Patients in the PROMs study completed baseline measures in clinic and were sent 
questionnaires to complete at home at 6 months, 1, 2 and 5 years following 
radiotherapy. Clinical assessments of NTE were collected at annual follow-up in all 
patients, and photographs were taken under standard conditions at post-surgical 
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pre-radiotherapy baseline and at 2 and 5 years post-randomisation for patients who 
had breast conserving surgery. The patient questionnaires included the i) EORTC 
QLQ-C30 core questionnaire and QLQ-BR23 breast-specific module [6, 16], from 
which the assessment of breast swelling over the previous 4 weeks (not at all, a little, 
quite a bit, very much) was used in this study of concordance, ii) Hospital Anxiety 
and Depression Scale [17], iii) 10-item Body Image Scale [18] and iv) 4 protocol-
specific questions asking patients to score “change in breast appearance”, “breast 
hardness/firmness”, “reduction in size of breast” and “change in skin appearance” 
since radiotherapy; the first three questions applying only to patients with conserved 
breasts, and all items scored on a 4-point scale (none, a little, quite a bit, very much). 
 
The annual clinical assessments of breast shrinkage, breast induration, 
telangiectasia and breast oedema were scored using the contralateral breast as a 
comparator and 4-point graded scales (none, a little, quite a bit, very much). Change 
in photographic breast appearance since radiotherapy was scored by a single team 
of 3 observers blind to patient identity, trial treatment allocation, year of follow-up and 
radiotherapy centre. The scoring method was validated in the START pilot trial [5]. 
Photographs at 2 and 5 years following radiotherapy were compared with a pre-
radiotherapy (post-surgery) baseline and an overall score allocated for change in 
photographic breast appearance in the treated breast based on change in size, 
shrinkage and shape, on a 3-point scale (no change, mild change, marked change). 
Post-mastectomy patients were included in the PROMs and clinical assessments but 
not in the photographic assessments. Individual NTE were mapped between the 
different assessment methods in order to compare corresponding outcomes, as 
shown in Table 1. 
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Statistical methods  
NTE assessments at all time-points in the trials were included in the comparison of 
radiotherapy schedules (i.e. from 6 months-5 years for the PROMs, from 1-5 years 
for the clinical assessments, and at 2 and 5 years for the photographs). Time to first 
NTE event (defined as “quite a bit” or “very much” for the PROMs and clinical 
assessments, and any change (mild or marked) in photographic breast appearance) 
was calculated from date of randomisation, and survival analysis methods used to 
compare radiotherapy schedules. Hazard ratios (HR) for the relative effects of the 
radiotherapy schedules in START-A were calculated for each NTE endpoint using 
Cox proportional hazards regression and compared between the different 
assessment methods using forest plots. Estimates of the α/β ratio for NTEs, which 
describes the sensitivity of normal tissues to fraction size, were obtained separately 
for the PROMs, clinician and photographic endpoints in START-A. Estimates of 
relative effects of the fractionation schedules in START-B are not presented in this 
paper as they do not contribute to the measurement of fraction sensitivity, only 
having two randomised groups in Trial B. HRs for the fractionation schedules in 
START-B have been published separately for the different NTE assessments, and 
showed consistent results [13-15].  
 
For the concordance analyses, data from START Trials A and B were combined, and 
only 2 and 5-year assessments included as these were the time-points at which all 
three NTE assessment methods were used in the trials. For all PROMs and 
clinically-assessed endpoints there were few patients in the highest grade category, 
so moderate and marked categories were combined, resulting in 3-point scales 
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corresponding to none, a little (“mild”), quite a bit / very much (“moderate / marked”); 
this also enabled comparison with the photographic assessments, which were 
scored on a similar 3-point scale. Corresponding NTE endpoints were matched 
between the PROMs, clinical and photographic assessments at each time point and 
compared on an individual patient basis using measures of concordance including 
percentage agreement (with 95% confidence interval, CI), weighted Kappa statistic 
(with 95%CI) and Bowker’s test of symmetry [19]. Guidelines for interpreting the 
value of the weighted Kappa statistic in terms of the strength of agreement are 
<0.20: poor, 0.21-0.40: fair, 0.41-0.6: moderate, 0.61-0.8: good, 0.81-1.00: very good 
[20]. Bowker’s test assesses the symmetry of a square table – i.e. whether there are 
more observations on one side of the diagonal than the other. The concordance 
analyses were also carried out stratifying on baseline patient characteristics such as 
age and quality of life scores (including anxiety and depression from the Hospital 
Anxiety and Depression Scale and body image from the Body Image Scale), to 
investigate whether these had any effect on the degree of concordance between 
NTE assessment methods.  
 
Results 
Of the 2208 women recruited into the overall START Trials PROMs study, self-
assessments of NTEs were available at 2 and/or 5 years for 1939 (88%) patients, of 
whom 1870 also had clinical assessments at the same time-points (85% of all 
patients in PROMs study). Patient characteristics at baseline for the 1870 patients in 
this analysis are shown in Table 2, of whom 1574/1870 (84.2%) had breast 
conserving surgery and 1444/1574 (91%) had photographic assessments at 2 and/or 
5 years. 
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Treatment effects on late NTE assessed by PROMs and by annual clinical 
assessment in START-A are shown side-by-side in Figure 1. Two test schedules 
(41.6 Gy and 39 Gy in 13 fractions) were compared with control (50 Gy in 25 
fractions) in START-A. Comparing HR for corresponding endpoints, it can be seen 
that the treatment effects were of a similar size for PROMs and clinical assessments, 
with overlapping confidence intervals. Treatment effects on late NTE assessed by 
PROMs and by photographs for overall change in breast appearance were also 
similar (Figure 2). α/β estimates (adjusted for prognostic factors) for overall change 
in breast appearance were 2.9 Gy (95%CI 0.7-5.1 Gy) for PROMs and 2.6 Gy 
(95%CI 1.3-3.9 Gy) for photographic assessments. α/β estimates for individual NTE 
endpoints from clinical assessments have been reported [14] (there was no clinical 
assessment of overall cosmesis in the START Trials).  
 
The comparison of overall rates of NTEs reported by PROMs and clinical 
assessments from START Trials A and B combined showed that patients reported a 
higher prevalence of breast changes (Figures 3a-d). Concordance between the 
assessments of corresponding NTEs on an individual patient basis was generally 
poor (Table 3). The lowest levels of percentage agreement between PROMs and 
clinicians were observed for breast induration / hardness (47% and 50% at 2 and 5 
years, respectively), and breast shrinkage (53% and 47% at 2 and 5 years). The 
highest level of percentage agreement between PROMs and clinicians was for 
breast swelling/oedema (78% and 86% at 2 and 5 years), but the overall prevalence 
of oedema was very low (Figure 3c). Weighted kappa statistics also highlighted the 
low agreement between methods, ranging from 0.05 for telangiectasia at 2 years 
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(indicating poor agreement) to 0.21 for each of breast shrinkage and breast oedema 
at 2 years (indicating fair agreement). Results of Bowker’s test of symmetry were 
highly statistically significant for all NTE endpoints, indicating a clear direction in the 
discordance of scoring between the different methods, with patients reporting more 
breast changes compared with clinical and photographic assessments (Table 3). 
There appeared to be no substantial differences in degree of concordance for 
individual NTE endpoints according to time since radiotherapy i.e. between 2 and 5 
years (Table 3). 
 
The comparison of PROMs and photographic assessments showed that patients 
reported a higher prevalence of overall change in breast appearance since 
radiotherapy and graded effects as more severe compared with the photographic 
assessments (Figure 3e). In testing concordance, agreement on an individual patient 
basis was low at 2 and 5 years (38% for each), with low weighted kappa values 
(0.09) and highly statistically significant discordance (p<0.001 for Bowker’s test of 
symmetry); Table 3. Concordance of PROMs with clinical and photographic 
assessments of NTE appeared to be unaffected by patient factors including age, 
breast size, surgical deficit, baseline HADS anxiety and depression and body image 
scores (table in web appendix). 
 
Discussion 
Concordance between PROMs and NTE assessments as scored by clinicians and 
from photographs on an individual patient basis was poor. Percentage agreement 
between PROMs and clinical assessments of specific NTEs was around 50%, 
indicating that in only half of the patients the NTE was graded in the same category 
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of severity corresponding to none, mild, moderate/marked. Agreement was even 
lower between PROMs and photographs, where less than 40% graded NTEs the 
same. In our study, patients scored NTEs more frequently and more severely than 
results from clinicians or photographs. Concordance did not appear to be affected by 
patient characteristics including psychological measures (anxiety and depression), 
body image and factors associated with risk of NTEs (age, breast size and surgical 
deficit). It may not be surprising that concordance between the assessment methods 
on an individual patient basis was poor; this has been consistently reported in other 
studies [21-24]. These differences in ratings reflect the different paradigms in which 
symptoms are perceived and rated; these include variance in context, values, 
expectations and methodological influences as well as the different sociocultural 
backgrounds of subjects and doctors [25]. Published comparisons of clinician and 
patient self-assessments show considerable variability between ratings, especially 
for more subjective symptoms and often report, as in our study, a relative 
underestimate by clinicians compared with patients (e.g. Basch et al [26], Bruner et 
al [27], Fromme et al [23], Groenwold et al [28], Quinten et al [29], Stephens et al 
[30], Velikova et al [24]). However, the concordance analysis of NTE assessments in 
the Cambridge intensity-modulated breast radiotherapy trial found the opposite, with 
clinicians and photographic assessments reporting more NTEs compared with 
patients, possibly because the study was done in  a single centre, with clinical 
ratings done by one person [31]. Others have shown more favourable rating of 
overall cosmesis following conservative treatment for breast cancer by patients 
compared with clinicians [32, 33], although these findings are not necessarily specific 
to late effects of radiotherapy. Kirchheiner et al [34] argued that some variation is 
“quite acceptable and comprehensible”, given the methodological differences 
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between morbidity scoring by clinicians and patient-reported symptoms. Clinical and 
patient symptom ratings are typically not designed to be interchangeable, given that 
they often have different values and purposes, with patient assessments inherently 
encompassing impact on quality of life.  
 
However, our study showed that despite the discordance between assessments on 
an individual basis, the three methods (PROMs, clinical and photographs) generated 
similar estimates of relative treatment effects on NTE within the trials [12, 14, 15]. 
The discriminatory power of different assessments was equally good, in that PROMs 
generated the same estimates of α/β value for NTE in START-A (around 3 Gy) as 
photographs and clinical assessments (data for α/β values of clinical assessments of 
NTEs previously published [14]). From the trial outcome perspective, this 
consistency of treatment effects adds considerable weight to the overall 
interpretation and conclusions of the trial. However, the PROMs reported here were 
selected from a large number of multidimensional items assessed as part of the 
START quality of life sub-study, most of which would not be expected to discriminate 
so clearly between the schedules in the START trials, but are of value in 
understanding the experience of treatment effects over time. The PROMs items 
included in this analysis of concordance were those directly relevant to the 
hypothesis under test in the clinical trial, and therefore most likely to be sensitive to 
randomised differences in radiotherapy dose intensity. The PROMs needed to have 
a recognisable relationship with the pathophysiology (atrophy, fibrosis) of NTE, 
broadly corresponding to clinical scoring of change in size (atrophy), shape and 
texture (oedema, fibrosis) of the breast and change in photographic breast 
appearance (atrophy, distortion/fibrosis). This is in contrast with other clinically 
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relevant domains, such as physical and social functioning, that explore the impact on 
different aspects of quality of life [6, 16].  
 
Clinicians are taught in training that symptomatology is the key to diagnosis, which 
they can only judge by listening to their patients and framing relevant questions. 
Clinicians act as surrogates for their patients in this context, so that if the relevant 
questions are known in advance (as they are in a clinical trial), there appears to be a 
good reason to prioritise the PROMs over the physical clinical assessments. Where 
physical signs are concerned, including breast size, shape and texture, this study 
suggests that patients are as sensitive as their doctors in scoring these changes too, 
provided the questions are framed appropriately. In this respect, it is possible to 
criticise our PROMs question, which asked patients to score changes since 
radiotherapy to the affected breast compared with the clinical assessment that 
compared the treated with the untreated breast at the time of the annual 
examination. Despite a variety of factors expected to influence how a woman 
responds to this question, the sensitivity to randomised dose indicates that the 
radiotherapy ‘signal’ was not lost. Doctors also develop their own frames of 
reference when assessing NTE, and the hundreds of clinical observers involved in 
scoring NTE in thousands of patients over a 10-year period, as in the START trials, 
necessarily contribute a lot of ‘noise’ in a scoring system. However, a disadvantage 
of reliance on PROMs in clinical trials is that they are traditionally labour-intensive to 
administer and generate large volumes of data, making heavy demands on trial 
management and statistical resources. Since modern data capture systems are 
increasingly able to collect outcome data directly from the patient (e.g. via an App), 
dispensing with clinical follow-up may appeal to patients as well as health services 
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operating under increasing pressures [35]. However, radiation effects are not viewed 
in isolation by patients and attention also needs to be paid to their concerns in the 
context of multi-modal treatments and adverse effects over time. Up to a third of 
patients report moderate or marked symptoms of the breast, arm and shoulder at 5 
years, which may warrant engagement and advice from their clinical teams [13]. 
Thus more preparation and after care is needed for the success of patient self-
management post-treatment and to improve quality of life [36]. Further, the 
acceptability of electronic symptom-reporting warrants evaluation in an aging 
population. 
 
Despite adding to the administrative burden of clinical trials, the photographic 
assessments of NTEs provide valuable information, not least because they are 
scored generally by the same small team of observers who are blind to patient 
identity, randomised treatment allocation, year of follow-up and participating hospital. 
As it is generally not possible to blind treatment allocation in radiotherapy trials the 
photographic assessments provide the only unbiased comparison of normal tissue 
effects between randomised groups. In addition, as photographs provide a 
permanent record of breast effects at a fixed point in time, the assessments can be 
validated by repeat scoring from different teams of observers [5], thus making the 
scoring more standardised than PROMs or clinical assessments from physical 
examination. Photographs can also be filed and stored for use in future translational 
research investigating adverse effects of radiotherapy. There are some 
disadvantages to the use of photographic assessments in clinical trials, including 
financial and staff resources required, and they can be disliked by patients, but these 
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are outweighed by the benefits of retaining an unbiased comparison of NTEs within 
radiotherapy trials.  
 
There is growing interest in investigating inherited risk factors for radiotherapy NTE, 
for which robust measures of NTE are needed that have a close relationship to the 
underlying pathophysiology [37], In this respect, the lack of concordance reported in 
this study is intriguing and potentially worrying. The prevalence and severity of NTEs 
reported by patients, clinicians and from photographs during follow-up were widely 
discordant in most cases. In trying to identify subgroups of patients with levels of 
NTE that are much more, or much less, severe than expected on the basis of known 
factors (breast size, radiotherapy dose etc.), it isn’t possible to judge whether the 
clinical and photographic assessments of NTE severity are more or less valid than 
the PROMs, hence making identification of potential cases (and controls) for 
translational studies very difficult. Perhaps much depends on how the NTE 
assessment questions to patients and clinicians are posed, something that this study 
does not address. 
 
In conclusion, the PROMs, clinical and photographic assessments of late NTE in the 
START trials generated consistent estimates of relative treatment effects between 
randomised groups, adding weight to the trials’ overall findings. Discordance in the 
prevalence rates of NTE reported by the patients, clinicians and photographs could 
be expected for a number of well-established reasons, but this does not undermine 
an argument for prioritising PROMs and photographic assessments of NTEs in 
breast radiotherapy trials. 
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Figure legends 
 
Figure 1: Comparisons between randomised radiotherapy schedules in START Trial 
A for PROMs and clinical assessments of specific normal tissue effects 
 
Figure 2: Comparisons between randomised radiotherapy schedules in START Trial 
A for PROMs and photographic assessments of overall change in breast appearance 
 
Figure 3: Comparison of 5-year PROMs, clinical and photographic assessments of 
specific normal tissue effects in START Trials A and B 
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Table 1: Clinical and photographic outcome measures of specific late normal tissue 
effects in the breast and the corresponding PROM 
 
Clinical assessment of late normal 
tissue effect in the treated breast 
Corresponding PROM used to test 
concordance with clinical or 
photographic assessment2 
Has the patient had any of the following 
adverse effects? Compare with 
contralateral breast1: 
 
Breast shrinkage 
Has your affected breast become smaller 
as a result of your radiotherapy?4 
Breast induration 
Has your affected breast become 
harder/firmer to the touch since your 
radiotherapy?4 
Breast oedema 
During the past four weeks, was the area 
of your affected breast swollen?5 
Telangiectasia 
Has the appearance of the skin in the 
area of your affected breast changed 
since your radiotherapy?4 
Has there been a change in 
photographic breast appearance 
compared with pre-radiotherapy 
baseline photograph?3 
Has the overall appearance of your 
affected breast changed, compared with 
the other side, as a result of your 
radiotherapy?4 
 
1
 Clinical assessments scored as none, a little, quite a bit, very much 
2
 PROMs scored as not at all, a little, quite a bit, very much 
3
 Photographic assessments scored as no change, mild change, marked change 
4
 Protocol-specified items included in the patient questionnaire booklet under the heading “Since your 
breast radiotherapy” 
5
 Question from the EORTC QLQ-BR23 breast cancer module 
Table
Table 2: Baseline characteristics of 1870 START Trial A and B patients with PROMs 
and clinical assessments of normal tissue effects at 2 and/or 5 years following 
radiotherapy 
 Number of patients (%) 
Age (years): mean (SD) [range] 57.0 (10.0) [27.1-86.0] 
Type of primary surgery 
  Breast conserving surgery 
  Mastectomy 
 
1574 (84.2) 
296 (15.8) 
Axillary surgery 
  None 
  Axillary clearance 
  Axillary sampling 
  Sentinel node biopsy 
 
55 (  2.9) 
1284 (68.7) 
495 (26.5) 
36 (  1.9) 
Adjuvant chemotherapy 
  No 
  Yes 
  Unknown 
 
1268 (67.8) 
598 (32.0) 
4 (  0.2) 
Tamoxifen 
  No 
  Yes 
  Unknown 
 
312 (16.7) 
1554 (83.1) 
4 (  0.2) 
Breast size 
  Small 
  Medium 
  Large 
  Unknown – not in photographic study  
 
154 (  8.2) 
1126 (60.2) 
228 (12.2) 
362 (19.4) 
Surgical deficit 
  Small 
  Medium 
  Large 
  Unknown – not in photographic study 
 
872 (46.6) 
496 (26.5) 
140 (  7.5) 
362 (19.4) 
Hospital Anxiety and Depression Scale  
Anxiety 
  Normal (0-7) 
  Borderline (8-10) 
  Case (11+) 
  Unknown 
 
1287 (68.8) 
322 (17.2) 
256 (13.7) 
5 (  0.3) 
Depression 
  Normal (0-7) 
  Borderline (8-10) 
  Case (11+) 
  Unknown 
 
1658 (88.7) 
152 (  8.1) 
52 (  2.8) 
8 (  0.4) 
Body Image Scale (10-items): median (IQR) [range] 3 (0-8) [0-30] 
 
SD = standard deviation; IQR = interquartile range 
Breast size and surgical deficit assessed from baseline photographs 
HADS scales range from 0-21 
Body Image Scale ranges from 0-30, where a higher score indicates more concerns; unknown for 79 
patients 
 
Table
1 
 
Table 3: Concordance between PROMs and clinical or photographic assessments of 
specific normal tissue effects at 2 and 5 years in START Trials A and B 
 
Clinicians Patients % 
agreement 
(95%CI) 
Weighted 
Kappa 
(95%CI) 
Bowker’s 
test of 
symmetry, 
p-value 
None A  
little 
Quite 
a bit 
/very 
much 
Breast shrinkage
1
 – 2 years 755/1413; 
53.4% 
(50.8-56.1%) 
0.21 
(0.17-0.25) 
<0.001 
None 566 335 83 
A little 107 158 70 
Quite a bit / very much 18 45 31 
Breast shrinkage
1
 – 5 years 579/1221; 
47.4% 
(44.6-50.3%) 
0.19 
(0.15-0.24) 
<0.001 
None 372 277 126 
A little 96 151 87 
Quite a bit / very much 18 38 56 
 
Breast induration / hardness
1
 – 2 years 676/1439 
47.0% 
(44.4-49.6%) 
0.12 
(0.08-0.16) 
<0.001 
None 493 379 136 
A little 112 152 73 
Quite a bit / very much 31 32 31 
Breast induration / hardness
1
 – 5 years 610/1222; 
49.9% 
(47.1-52.8%) 
0.12 
(0.07-0.16) 
<0.001 
None 482 295 94 
A little 121 105 40 
Quite a bit / very much 22 40 23 
 
Breast oedema / swelling
1
 – 2 years 1144/1465; 
78.1% 
(75.9-80.2%) 
0.21 
(0.15-0.26) 
0.017 
None 1092 146 21 
A little 109 51 9 
Quite a bit / very much 16 20 1 
Breast oedema / swelling
1
 – 5 years 1089/1260; 
86.4% 
(84.4-88.2%) 
0.10 
(0.04-0.17) 
0.003 
None 1076 86 19 
A little 54 13 3 
Quite a bit / very much 6 3 0 
 
Telangiectasia / change in skin appearance
2
 – 2 years 959/1721; 
55.7% 
(53.3-58.1%) 
0.05 
(0.02-0.07) 
<0.001 
None 911 572 134 
A little 32 42 11 
Quite a bit / very much 6 7 6 
Telangiectasia / change in skin appearance
2
 – 5 years 900/1446; 
62.2% 
(59.7-64.7%) 
0.08 
(0.04-0.12) 
<0.001 
None 859 369 90 
A little 47 30 16 
Quite a bit / very much 13 11 11 
 
Photographs 
Overall change in breast appearance
1
 – 2 years 489/1290; 
37.9% 
(35.3-40.6%) 
0.09 
(0.06-0.11) 
<0.001 
None 331 525 130 
Mild 56 141 78 
Marked 4 8 17 
Overall change in breast appearance
1
 – 5 years 409/1064; 
38.4% 
(35.5-41.4%) 
0.09 
(0.06-0.12) 
<0.001 
None 258 344 123 
Mild 66 140 108 
Marked 5 9 11 
 
CI = confidence interval 
1
 breast conserving surgery patients only 
2
 breast conserving surgery and mastectomy patients 
Table
Web Appendix: Concordance between PROMs and clinical or photographic assessments of specific normal tissue effects at 5 years stratified by baseline 
patient characteristics in START Trials A and B 
 Breast shrinkage
1
 Breast induration/hardness
1
 Breast oedema/swelling
1
 Telangiectasia/change in 
skin appearance
2
 
Overall change in breast 
appearance
1
 
% agreement 
(95%CI) 
Weighted 
Kappa (95%CI) 
% agreement 
(95%CI) 
Weighted 
Kappa (95%CI) 
% agreement 
(95%CI) 
Weighted 
Kappa 
(95%CI) 
% agreement 
(95%CI) 
Weighted 
Kappa 
(95%CI) 
% 
agreement 
(95%CI) 
Weighted 
Kappa 
(95%CI) 
Age 
<50 years 
 
>50 years 
 
43.7  
(37.5-50.0) 
48.4  
(45.2-51.6) 
 
0.22  
(0.14-0.31) 
0.20  
(0.15-0.25) 
 
47.4  
(41.2-53.8) 
50.6  
(47.4-53.8) 
 
0.09  
(0.01-0.17) 
0.13  
(0.08-0.18) 
 
N/A 
 
86.9  
(84.6-88.9) 
 
N/A 
 
0.12  
(0.05-0.20) 
 
56.7  
(50.9-62.3) 
63.7  
(60.9-66.5) 
 
0.06  
(0.001-0.12) 
0.09  
(0.05-0.14) 
 
37.6 
(30.9-44.8) 
39.2 
(35.9-42.7) 
 
0.05 
(0-0.12) 
0.11 
(0.07-0.15) 
Breast size 
Small 
 
Medium 
 
Large 
 
 
52.8  
(43.7-61.8) 
48.9  
(45.5-52.2) 
37.8 
(30.8-45.5) 
 
0.13  
(0-0.26) 
0.22  
(0.17-0.27) 
0.10  
(0-0.21) 
 
59.8  
(50.5-68.5) 
49.8  
(46.4-53.1) 
44.6 
(37.2-52.3) 
 
0.06  
(0-0.19) 
0.11 
(0.05-0.16) 
0.10  
(0-0.21) 
 
N/A 
 
87.1  
(84.6-89.2) 
80.5  
(73.9-85.8) 
 
N/A 
 
0.06  
(0-0.13) 
0.20  
(0.05-0.36) 
 
N/A 
 
62.9 
(59.6-66.1) 
48.7 
(41.3-56.0) 
 
N/A 
 
0.05  
(0.01-0.10) 
0.07 
(0-0.16) 
 
41.2 
(32.2-50.8) 
38.2 
(34.7-41.7) 
36.9 
(29.5-45.0) 
 
0.02 
(0-0.06) 
0.08 
(0.05-0.12) 
0.06 
(0-0.17) 
Surgical deficit 
Small 
 
Medium 
 
Large 
 
 
50.9 
(47.1-54.7) 
43.9  
(38.8-49.1) 
39.3 
(30.3-49.0) 
 
0.21  
(0.15-0.26) 
0.16 
(0.08-0.23) 
0.12 
(0-0.24) 
 
50.1 
(46.3-53.8) 
53.0 
(47.7-58.1) 
40.0 
(30.9-49.8) 
 
0.10  
(0.04-0.15) 
0.20 
(0.11-0.29) 
N/A 
 
84.9 
(82.1-87.4) 
90.8  
(87.3-93.4) 
82.0 
(73.3-88.4) 
 
0.06  
(0-0.14) 
0.28 
(0.12-0.44) 
N/A 
 
62.6 
(58.9-66.2) 
60.8 
(55.7-65.8) 
60.0 
(50.2-69.1) 
 
0.08 
(0.03-0.13) 
0.03 
(0-0.10) 
0.10 
(0-0.23) 
 
40.5 
(36.7-44.6) 
36.9 
(31.9-42.3) 
28.9 
(20.3-39.1) 
 
0.10 
(0.06-0.14) 
0.08 
(0.01-0.14) 
N/A 
HADS anxiety 
0-7 (normal) 
 
8-10 
(borderline) 
>11 (case) 
 
 
50.9 
(47.5-54.3) 
43.2 
(36.4-50.3) 
35.0 
(27.7-43.0) 
 
0.22 
(0.17-0.27) 
0.14 
(0.05-0.22) 
0.13 
(0.04-0.22) 
 
52.2 
(48.8-55.6) 
46.1 
(39.2-53.2) 
42.5 
(34.8-50.1) 
 
0.12 
(0.07-0.18) 
0.12 
(0.03-0.22) 
0.09 
(0-0.19) 
 
89.0 
(86.7-90.9) 
81.2 
(75.2-86.1) 
N/A 
 
0.09 
(0-0.17) 
0.23 
(0.08-0.38) 
N/A 
 
65.6 
(62.6-68.5) 
56.7 
(50.3-63.0) 
51.1 
(43.7-58.4) 
 
0.07 
(0.03-0.12) 
0.10 
(0-0.20) 
0.08 
(0-0.17) 
 
40.3 
(36.8-43.9) 
34.8 
(28.0-42.2) 
32.1 
(24.3-40.9) 
 
0.09 
(0.05-0.13) 
0.08 
(0.01-0.15) 
0.07 
(0-0.15) 
HADS 
depression 
0-7 (normal) 
 
8-10 
(borderline) 
>11 (case) 
 
 
 
48.2 
(45.2-51.2) 
40.9 
(30.7-51.9) 
43.7 
(26.8-62.1) 
 
 
0.19 
(0.15-0.24) 
0.15 
(0.01-0.29) 
0.26 
(0.07-0.46) 
 
 
51.4 
(48.4-54.4) 
31.8 
(22.5-42.7) 
46.9 
(29.5-65.0) 
 
 
0.13 
(0.08-0.18) 
N/A 
 
0.21 
(0-0.48) 
 
 
87.9 
(85.8-89.7) 
70.0 
(59.3-79.0) 
N/A 
 
 
0.13 
(0.06-0.21) 
N/A 
 
N/A 
 
 
64.5 
(61.9-67.1) 
43.2 
(34.0-53.0) 
37.5 
(23.2-54.2) 
 
 
0.09 
(0.04-0.13) 
0.06 
(0.02-0.11) 
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Dear Dr Jena 
 
Do patient-reported outcome measures agree with clinical and 
photographic assessments of normal tissue effects after breast 
radiotherapy? The experience of the Standardisation of Breast 
Radiotherapy (START) Trials in early breast cancer 
 
We would be grateful if you would please consider our manuscript for 
publication in Clinical Oncology, along with a related manuscript from 
Mukesh Mukesh and Charlotte Coles. We are submitting the manuscripts as 
a pair as the analyses were done in parallel, and each provides a different 
perspective on the measurement of normal tissue effects in breast 
radiotherapy trials. The manuscripts compare the assessments of normal 
tissue effects carried out within the START and Cambridge IMRT trials, and 
assess the concordance of patient-reported outcomes with clinical and 
photographic assessments, on an individual patient level as well as for 
overall treatment comparisons.  
 
Although there is an extensive literature on the comparison of patient and 
doctor assessments in general, there is little available on assessments of 
long-term adverse effects of radiotherapy specifically. Given that the 
collection of data on late normal tissue effects forms a major part of data 
collection in radiotherapy trials, it is pertinent to investigate differences and 
similarities between assessment methods, and to question whether all are 
strictly necessary in future trials. The START Trials provide a large dataset 
enabling such concordance analyses, and we believe that our findings will 
provide valuable information to those designing and interpreting the findings 
of radiotherapy trials.  
 
Kind regards. 
 
Yours sincerely 
 
 
 
John Yarnold 
Professor of Clinical Oncology 
 
Dr Rajesh Jena 
Assistant Editor, Clinical Oncology 
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